Sema4 shareholders approve GeneDx acquisition, authorize share increase to 1B

GeneDx Holdings Corp.

Stockholders approved shares for GeneDx acquisition: 178,157,301 for, 104,365 against.
Approved PIPE investment issuance: 178,106,518 for, 153,719 against.
Approved charter amendment increasing authorized Class A common from 380M to 1B shares.
Elected three Class I directors to serve three-year terms expiring 2025.
Ratified Ernst & Young as independent auditor for fiscal year 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.